Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s244, 2023. DOI: 10.25251/skin.7.supp.244. Disponível em: https://skin.dermsquared.com/skin/article/view/2354. Acesso em: 22 may. 2026.